Thomas Stankovich - 15 Jun 2021 Form 4 Insider Report for ReShape Lifesciences Inc. (RSLS)

Reporting relationship: Chief Financial Officer
Issuer ticker: RSLS
Reported as of: 15 Jun 2021
Net transaction value: -$14,137
SEC form: 4
Accepted by SEC: 17 Jun 2021, 16:06:20 UTC
Next SEC filing: 17 Sep 2021
Source filing: View source filing
Reporting owner signature: /s/ Thomas Stankovich

Key filing fact

Thomas Stankovich filed Form 4 for ReShape Lifesciences Inc. (RSLS) on 17 Jun 2021.

Key facts

This page summarizes Thomas Stankovich's Form 4 filing for ReShape Lifesciences Inc. (RSLS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Jun 2021, 16:06.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: -$14,137.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RSLS transaction

Common Stock, $0.001 par value per share

Disposed to Issuer

Transaction value: $14,137
Shares: -4,635
Change %: -100%
Price: $3.05^*
Shares after: 0
Date: 15 Jun 2021
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Disposed of pursuant to the Agreement and Plan of Merger by and among the issuer, Obalon Therapeutics, Inc. ("Obalon"), and Optimus Merger Sub, Inc., which became effective on June 15, 2021, in exchange for 2,613 shares of common stock of Obalon having a market value of $3.05 per share at the effective time of the merger.